Precision BioSciences Inc. [DTIL] shares are down more than -38.52% this year and recently decreased -0.13% or -$1.38 to settle at $10.23. DTIL has a short ratio of 3.36. This implies that the market is currently less bearish on the outlook for DTIL.
On 24, November 2020, Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference. According to news published on Yahoo Finance, Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020.
Analyst Birdseye View:
The most recent analyst activity for Precision BioSciences Inc. [NASDAQ:DTIL] stock was on April 03, 2020, when it was Downgrade with a Neutral rating from Goldman, which also lowered its 12-month price target on the stock from $24 to $7. Before that, on July 27, 2020, BTIG Research Recapitulated a Buy rating and elevated its amount target to $16. On March 05, 2020, Stifel Initiated a Buy rating and boosted its price target on this stock to $21. On February 25, 2020, William Blair Initiated an Outperform rating. On August 09, 2019, BTIG Research Initiated a Buy rating and increased its price target to $22. On July 16, 2019, H.C. Wainwright Initiated a Buy rating and boosted its amount on this stock to $21. On April 22, 2019, JP Morgan Initiated an Overweight rating. Jefferies elevated its amount target by recapitulating a higher weight for this stock.
In the past 52 weeks of trading, this stock has oscillated between a low of $4.45 and a peak of $23.67. Right now, the middling Wall Street analyst 12-month amount mark is $18.00. At the most recent market close, shares of Precision BioSciences Inc. [NASDAQ:DTIL] were valued at $10.23. According to the average price forecast, investors can expect a potential return of 1.61%.
Precision BioSciences Inc. [NASDAQ:DTIL] most recently reported quarterly sales of 7.36 billion, which represented growth of 51.00%. This publicly-traded organization’s revenue is $111,749 per employee, while its income is -$466,719 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -49.69, -104.20, -97.83 and -104.20 respectively.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 9.13 points at 1st support level, the second support level is making up to 8.02. But as of 1st resistance point, this stock is sitting at 11.46 and at 12.68 for 2nd resistance point.
Precision BioSciences Inc. [DTIL] reported its earnings at -$0.5 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.66/share signifying the difference of 0.16 and 24.20% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.63 calling estimates for -$0.59/share with the difference of -0.04 depicting the surprise of -6.80%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Precision BioSciences Inc. [NASDAQ:DTIL] is 2.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 6.72. Now if looking for a valuation of this stock’s amount to sales ratio it’s 26.23 and it’s amount to book ratio is 5.14.
The most recent insider trade was by Heery Christopher, Chief Medical Officer, and it was the purchase of 2485.0 shares on Dec 19.